Novo still expecting EU Wegovy approval around the New Year

Before the turn of the year, Novo Nordisk predicts it will have received marketing approval for its obesity drug Wegovy in Europe.

Photo: Novo Nordisk / PR

There is still hope that obesity treatment Wegovy will be authorized for the European market before the end of the year.

At least, that is what Novo Nordisk's CEO Lars Fruergaard Jørgensen said in an interview with Bloomberg News, as reported by the media relations team at the Danish pharmaceutical firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs